Compare
Bio Essence Corp vs Lipocine Inc. vs Dianthus Therapeutics, Inc. vs Rani Therapeutics Holdings, Inc.
| Latest fiscal year | Bio Essence Corp BIOE | Lipocine Inc. LPCN | Dianthus Therapeutics, Inc. DNTH | Rani Therapeutics Holdings, Inc. RANI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.90M | $1.98M | $2.04M | $1.63M |
| Revenue growth (YoY) | +485.8% | -82.3% | -67.3% | +58.9% |
| Gross margin | 75.3% | n/a | n/a | n/a |
| Operating margin | 47.4% | -524.7% | n/m | n/m |
| Net margin | 47.2% | -487.1% | n/m | n/m |
| Net income | $896.2K | -$9.63M | -$162.34M | -$40.95M |
| EPS (Diluted) | n/a | -$1.69 | -$4.20 | -$0.45 |
| Operating cash flow | $1.57M | -$9.76M | -$129.06M | -$18.71M |
| Free cash flow | n/a | n/a | n/a | -$18.80M |
| Cash & equivalents | n/a | $5.21M | $51.09M | $18.62M |
| Total assets | $422.5K | $17.01M | $530.92M | $58.62M |
| Total liabilities | $2.50M | $2.53M | $37.52M | $17.11M |
| Shareholders' equity | -$2.07M | $14.48M | $493.40M | $33.01M |
| Return on year-end equity | n/a | -66.5% | -32.9% | -124.1% |
| Shares outstanding | 38.01M | 6.16M | 43.22M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Bio Essence Corp | Lipocine Inc. | Dianthus Therapeutics, Inc. | Rani Therapeutics Holdings, Inc. |
|---|---|---|---|---|
| Latest | $1.90M Ended 2025-12-31 | $1.98M Ended 2025-12-31 | $2.04M Ended 2025-12-31 | $1.63M Ended 2025-12-31 |
| 1 year earlier | $323.9K Ended 2024-12-31 | $11.20M Ended 2024-12-31 | $6.24M Ended 2024-12-31 | $1.03M Ended 2024-12-31 |
| 2 years earlier | $551.5K Ended 2023-12-31 | -$2.85M Ended 2023-12-31 | $2.83M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $621.6K Ended 2022-12-31 | $500.0K Ended 2022-12-31 | n/a | $0 Ended 2022-12-31 |
| 4 years earlier | $888.0K Ended 2021-12-31 | $16.14M Ended 2021-12-31 | n/a | $2.72M Ended 2021-12-31 |